Skip to content

One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection

One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02734134
Enrollment
343
Registered
2016-04-12
Start date
2016-05-18
Completion date
2026-01-07
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection

Keywords

Periprosthetic joint infection

Brief summary

The purpose of this study is to compare the outcomes of two different treatment options commonly used to manage periprosthetic joint infection (PJI), an infection around the artificial knee or hip.

Detailed description

Total joint arthroplasty (TJA) is a very common and successful procedure, and is expected to become more prevalent in the upcoming years. However, despite its success, TJA is associated with some complications, including periprosthetic joint infection (PJI). PJI is a devastating complication that is associated with marked patient morbidity and mortality and is an immense economic burden. Although the rate of PJI following a TJA is low, the burden is rising exponentially due to health complications and treatment costs. There are two common types of surgical treatments that can be used to treat chronic PJI, a two-stage exchange arthroplasty and a one-stage exchange arthroplasty. During a two-stage exchange arthroplasty, the implants are removed, infected tissues are debrided and a temporary antibiotic impregnated spacer fashioned from polymethylmethacrylate is placed (stage one). Afterwards the patient undergoes many weeks of intravenous antibiotics, followed by reimplantation at a later date (stage two). During the time between the first and second stage of the revision patients are often immobile, experience severe pain due to a lack of functioning joint, and may experience systemic toxicity associated with the administration of antibiotics. In a one stage exchange arthroplasty, the infected prosthesis is removed, infected tissues are debrided, and a new prosthesis is reimplanted during the same procedure. While the two-stage exchange arthroplasty is the preferred method of treatment for chronic PJI in North America, the one-stage exchange arthroplasty is the method of choice in Europe and some centers have reported comparable results in terms of success for one-stage exchange to two-stage exchange arthroplasty. However, there has been no randomized, prospective, controlled study to date that compares one-stage exchange to two-stage exchange arthroplasty. Because of the lack of comparative outcome reports, and the perceived higher rate of failure of one-stage exchange arthroplasty, surgeons in North America prefer to perform the traditional two-stage exchange arthroplasty for management of chronic PJI. Several teams have succeeded in performing a one-stage exchange arthroplasty in selected patients, but this procedure has not gained much popularity in the US. The purpose of this study is to investigate the outcome of one-stage and two-stage exchange arthroplasty for the management of patients with chronic PJI. The hypothesis of this study is that one-stage exchange arthroplasty, if performed in the appropriate patient population, carries a similar success rate for the treatment of chronic PJI as two-stage exchange arthroplasty and avoids many of the problems associated with two-stage exchange arthroplasty.

Interventions

PROCEDUREOne-stage exchange joint replacement surgery
PROCEDURETwo-stage exchange joint replacement surgery

Sponsors

OrthoCarolina Research Institute, Inc.
Lead SponsorOTHER
The Cleveland Clinic
CollaboratorOTHER
Hospital for Special Surgery, New York
CollaboratorOTHER
Rothman Institute at Thomas Jefferson University
CollaboratorUNKNOWN
Midwest Orthopaedics Rush University Medical Center
CollaboratorUNKNOWN
Vanderbilt University
CollaboratorOTHER
Emory University
CollaboratorOTHER
University of Iowa
CollaboratorOTHER
Carilion Clinic
CollaboratorOTHER
University of Southern California
CollaboratorOTHER
Ochsner Health System
CollaboratorOTHER
Cleveland Clinic Florida
CollaboratorOTHER
University of Utah
CollaboratorOTHER
University of California, San Francisco
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years old * Patients who speak English and are willing to sign the consent form * Patients with chronic infection of a total knee or total hip arthroplasty, defined as: * A sinus communicating with the prosthesis * Two positive cultures obtained from the prosthesis * 3 of 5 criteria: (i) Elevated erythrocyte sedimentation rate (ESR) (\>30mm/jr) and c-reactive protein (CRP) (\>10mg/L) (ii) Elevated synovial leukocyte count (\>3000 cells/µL) or change of ++ on leukocyte esterase strip (iii) Elevated synovial neutrophil percentage (\>80%) (iv) One positive culture (v) Positive histological analysis of periprosthetic tissue (\>5 neutrophils per high power field in 5 high power fields x400) * Patients with a previous irrigation and debridement for periprosthetic infection

Exclusion criteria

* Culture negative infections whereby the infecting organism has not identified * Patients with systemic sepsis who require emergent surgery * Patients with extensive soft tissue involvement that would preclude the closure of the wound after reimplantation, if the patient were to undergo the one-stage exchange * Patients with acute PJI or acute hematogenous PJI, defined as: * Presentation of systems \<4 weeks from index procedure * Presentation of systems \<4 week duration * Fungal infections * Resistant organisms not sensitive to available IV antibiotics, oral antibiotics, or heat stable antibiotic additives to bone cement with documented elution characteristics * Revision surgery or previous two-stage reimplant * HIV positive patients or patients on chemotherapy

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of infection1 year following treatmentThe primary outcome measured will be the recurrence of infection by the same organism or reinfection with a new organism as determined by the criteria using the International Consensus Meeting on PJI (1 year follow-up).

Secondary

MeasureTime frameDescription
Health Related Quality of Health2 years following surgeryAll patients will complete the Veteran's Rand - 12 (VR-12) which is a general health measure. The VR-12 also yields a health utility measure that can be used to calculate quality-adjusted life years in an economic cost-utility analysis.
Patient-Reported Functional Outcomes2 years following surgeryHip patients will complete the Hip disability and Osteoarthritis Outcome Score (HOOS), Junior which is a region-specific measure of pain and function of the hip.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORThomas K Fehring, MD

Attending Hip & Knee Surgeon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026